A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Alzamend Neuro, Inc.
ALZN
$3M
Mkt Cap
$1.70
+1.19%
Business description not available.
| Metric | TTM | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | 0 | - | - |
| Net Income | 0 | -5.0M | -4.4M |
| EPS | $0.00 | $-3.14 | $-2.69 |
| Free Cash Flow | 0 | -2.7M | -2.3M |
| ROIC | - | -194.3% | -425.3% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.45 | 1.21 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | 0 | -5.0M | -4.4M |
| Operating Margin | 0.0% | - | - |
| ROE | 0.0% | -356.1% | -536.7% |
| Shares Outstanding | 5M | 2M | 2M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | 1.1M | 1.3M | 1.3M |
| SG&A | 3.4M | 3.6M | 3.6M |
| EBIT | -4.4M | -5.0M | 0 |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -4.4M | -5.0M | 0 |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | N/M | -194.3% | N/A |
| ROE | -536.7% | -356.1% | 0.0% |
| ROA | -243.1% | -213.5% | 0.0% |
| Cash Flow | |||
| Op. Cash Flow | -2.3M | -2.7M | 0 |
| Free Cash Flow | -2.3M | -2.7M | 0 |
| Owner Earnings | -4.1M | -4.7M | -2.0M |
| CapEx | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | 0 |
| D&A | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 1.8M | 2.0M | 2.0M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | 0 |
| Cash & Equiv. | 90K | 1.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | 1.21 | 0.45 | 0.00 |
| Interest Coverage | -317.7 | -34.8 | -34.8 |
| Equity | 822K | 2.0M | 0 |
| Total Assets | 1.8M | 2.9M | 0 |
| Total Liabilities | 992K | 900K | 900K |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -12M | -17M | -17M |
| Working Capital | 822K | 2.0M | 2.0M |
| Current Assets | 1.8M | 2.9M | 2.9M |
| Current Liabilities | 992K | 900K | 900K |
| Per Share Data | |||
| EPS | -2.69 | -3.14 | 0.00 |
| Owner EPS | -2.53 | -2.95 | -0.42 |
| Book Value | 0.50 | 1.25 | 0.00 |
| Cash Flow/Share | -1.43 | -1.69 | 0.00 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 1.6M | 1.6M | 4.8M |
| Valuation | |||
| P/E Ratio | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 8.1M |
| Avg. Price | 0.00 | 0.00 | 1.70 |
| Year-End Price | 0.00 | 0.00 | 1.70 |
Alzamend Neuro, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Alzamend Neuro, Inc. (ALZN) has a 5-year average return on invested capital (ROIC) of -194.3%. This is below average and may indicate limited pricing power.
Alzamend Neuro, Inc. (ALZN) has a market capitalization of $8M. It is classified as a small-cap stock.
Alzamend Neuro, Inc. (ALZN) does not currently pay a regular dividend.
Alzamend Neuro, Inc. (ALZN) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Alzamend Neuro, Inc. (ALZN) has a debt-to-equity ratio of 0.45. This indicates a conservatively financed balance sheet.
Alzamend Neuro, Inc. (ALZN) reported earnings per share (EPS) of $-3.14 in its most recent fiscal year.
Alzamend Neuro, Inc. (ALZN) has a return on equity (ROE) of -356.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Alzamend Neuro, Inc. (ALZN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Alzamend Neuro, Inc. (ALZN) has a book value per share of $1.25, based on its most recent annual SEC filing.